Supplementary Figure 7 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer

Jeffrey S. Damrauer; Kyle R. Roell; Markia A. Smith; Xuezheng Sun; Erin L. Kirk; Katherine A. Hoadley; Halei C. Benefield; Gopa Iyer; David B. Solit; Matthew I. Milowsky; William Y. Kim; Matthew E. Nielsen; Sara E. Wobker; Guido Dalbagni; Hikmat Al‐Ahmadie; Andrew F. Olshan; Bernard H. Bochner; Helena Furberg; Melissa A. Troester; Eugene J. Pietzak

doi:10.1158/1078-0432.27183497

Abstract

Supplemental Figure 7 shows PDL1 (CD274) Expression, PD1 (PDCD1) Expression, and CTLA4 Expression by UROMOL Subclasses in MSK and UNC cohorts and RFS (by high, medium, low tertiles) in MSK, UROMOL, & Northwestern Cohorts.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Damrauer et al. (2024) studied this question.

synapsesocial.com/papers/68e55b6ce2b3180350ef9496 https://doi.org/10.1158/1078-0432.27183497

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 7 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer

Abstract

Discussion

Cite This Study

Supplementary Figure 7 from Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading